GVOKE HypoPen
Posted over 3 years ago by Lori Kelley
This announcement has 1 attachment:
Hello,
I hope everyone is enjoying the warm Pennsylvania weather! My name is Michael and I am emailing in regards to your students living with diabetes. Many schools in Pennsylvania have started to discuss the Gvoke Hypopen with their students, and I wanted to provide information for all of you.
It is an epi-pen filled with liquid glucagon in the event a student with diabetes is having severe low blood sugar. Attached is a quick flyer highlighting the pen. Below is an image of how it works, as well as two links to our website for more information.
How to Use Gvoke | Request a Demo HypoPen
If you have any questions for me, would like to schedule a zoom meeting with me to discuss, or would like demo pens sent to your school free of cost, please contact me at the information below. I look forward to helping the state of Pennsylvania keep its students safe!
Sincerely,
|
Michael O’Connor Account Representative, Inside Sales Xeris Pharmaceuticals, Inc. Office: 312-380-7282 | Cell : 847-848-3455 Fax: 312-277-0964 180 N. Lasalle Street, Suite 1600, Chicago, IL 60601
 |
INDICATION AND IMPORTANT SAFETY INFORMATION:
GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.
IMPORTANT SAFETY INFORMATION
Contraindications
GVOKE is contraindicated in patients with pheochromocytoma, insulinoma, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.
Warnings and Precautions
GVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously. Allergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction.
GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose.
Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas has been reported postmarketing following continuous glucagon infusion and resolved with discontinuation of the glucagon. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks. Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia.
Adverse Reactions
Most common (≥5%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.
Drug Interactions
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin.
Go to https://www.gvokeglucagon.com/pdf/gvoke-prescribing-information.pdf to see Important Information about Gvoke.